Last reviewed · How we verify
H2 Receptor Antagonist
H2 receptor antagonists block histamine H2 receptors on gastric parietal cells to reduce stomach acid secretion.
H2 receptor antagonists block histamine H2 receptors on gastric parietal cells to reduce stomach acid secretion. Used for Peptic ulcer disease, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.
At a glance
| Generic name | H2 Receptor Antagonist |
|---|---|
| Also known as | Famotidine, H2RA |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | H2 receptor antagonist |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
These drugs competitively inhibit histamine binding to H2 receptors, which normally stimulate gastric acid production. By blocking this pathway, H2 antagonists decrease both basal and stimulated acid secretion, raising gastric pH and allowing ulcers and acid-related conditions to heal. They are used for peptic ulcer disease, gastroesophageal reflux disease (GERD), and other acid-related disorders.
Approved indications
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Constipation
- Dizziness
- Gynecomastia (with long-term use)
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H2 Receptor Antagonist CI brief — competitive landscape report
- H2 Receptor Antagonist updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI